Loss of function of the candidate tumor suppressor prox1 by RNA mutation in human cancer cells

Neoplasia

Volumn 8, Issue 12, 2006, Pages 1003-1010

  Takahashi, Meiko ^a   Yoshimoto, Takanobu ^a   Shimoda, Masayuki ^a   Kono, Tomoya ^a   Koizumi, Masayuki ^a   Yazumi, Shujiro ^a   Shimada, Yutaka ^a   Doi, Ryuichiro ^a   Chiba, Tsutomu ^a   Kubo, Hajime ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Asymmetrical cell division; Cancer; Prox1; RNA mutation; Tumor suppressor gene

Indexed keywords

ADENOSINE; COMPLEMENTARY DNA; GENOMIC DNA; HOMEODOMAIN PROTEIN; INOSINE; MESSENGER RNA; PROTEIN PROX1; TETRACYCLINE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG INHIBITION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 33845576594     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06595     Document Type: Article

References (25)

1. Vogelstein B and Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med 10, 789-799.
2. Murrel A, Rakyan VK, and Beck S (2005). From genome to epigenome. Hum Mol Genet 14, R3-R10.
3. Scholzova E, Malik R, Sevcik J, and Kleibl Z (2006). RNA regulation and cancer development. Cancer Lett May 2; [Epub ahead of print].
4. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, and Mazoyer S (2002). The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11, 2805-2814.
5. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, and Slack FJ (2005). RAS is regulated by the let-7 microRNA family. Cell 120, 635-647.
6. Hong YK and Detmar M (2003). Master regulator of the lymphatic vasculature phenotype. Cell Tissue Res 314, 85-92.
7. Wang J, Kilic G, Aydin M, Burke Z, Oliver G, and Sosa-Pineda B (2005). Prox1 activity controls pancreas morphogenesis and participates in the production of "secondary transition" pancreatic endocrine cells. Dev Biol 286 (1), 182-194.
8. Sosa-Pineda B, Wigle JT, and Oliver G (2000). Hepatocyte migration during liver development requires Prox1. Nat Genet 25, 254-255.
9. Dyer MA, Livesey FJ, Cepko CL, and Oliver G (2003). Prox1 function controls progenitor cell proliferation and horizontal cell genesis in the mammalian retina. Nat Genet 34 (1), 53-58.
10. Wigle JT, Chowdhury K, Gruss P, and Oliver G (1999). Prox1 function is crucial for mouse lens-fibre elongation. Nat Genet 21, 318-322.
11. Shimoda M, Takahashi M, Yoshimoto T, Kono T, Ikai I, and Kubo H (2006). A homeobox protein prox1 is involved in the differentiation, proliferation and prognosis in hepatocellular carcinoma. Clin Cancer Res 12, 6005-6011.
12. Nagai H, Li Y, Hatano S, Toshihito O, Yuge M, Ito E, Utsumi M, Saito H, and Kinoshita T (2003). Mutations and aberrant DNA methylation of the PROX1 gene in hematologic malignancies. Genes Chromosomes Cancer 38 (1), 13-21.
13. Morrison S and Kimble J (2006). Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 441, 1068-1074.
14. Caussinus E and Gonzalez C (2005). Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster. Nat Genet 37, 1125-1129.
15. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, Lohse CM, and Fields AP (2005). Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65, 8905-8911.
16. Wang Q, Khillan J, Gadue P, and Nishikura K (2000). Requirement of the RNA editing deaminase ADAR1 gene for embryonic erythropoiesis. Science 290, 1765-1768.
17. Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, and Seeburg PH (1993). RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell 75, 1361-1370.
18. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, and Knowles DM (2006). Mutational analysis of PRDM1 indicates a tumor suppressor role in diffuse large B-cell lymphomas. Blood 107, 1090-1100.
19. Klimek-Tomczak K, Mikula M, Dzwonek A, Paziewska A, Karczmarski J, Hennig E, Bujnicki JM, Bragoszewski P, Denisenko O, Bomsztyk K, et al. (2006). Editing of hnRNP K protein mRNA in colorectal adenocarcinoma and surrounding mucosa. Br J Cancer 94, 586-592.
20. Bourara K, Litvak S, and Araya A (2000). Generation of G-to-A and C-to-U changes in HIV-1 transcripts by RNA editing. Science 289, 1564-1566.
21. Sharma PM, Bowman M, Madden SL, Rauscher FJ III, and Sukumar S (1994). RNA editing in the Wilms tumor susceptibility gene, WT1. Genes Dev 8, 720-731.
22. Beghini A, Ripamonti CB, Peterlongo P, Roversi G, Cairoli R, Morra E, and Larizza L (2000). RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum Mol Genet 9, 2297-2304.
23. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, and Innerarity TL (1995). Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA 92, 8483-8487.
24. Yamanaka S, Poksay KS, Arnold KS, and Innerarity TL (1997). A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Genes Dev 11, 321-333.
25. Greeve J, Lellek H, Apostel F, Hundoegger K, Barialai A, Kirsten R, Welker S, and Greten H (1999). Absence of APOBEC-1 mediated mRNA editing in human carcinomas. Oncogene 18, 6357-6366.